Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Frankfurt – page 35

978 clinical trials in Frankfurt, Germany across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Frankfurt at a glance
978
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

978 trials in Frankfurt

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Obesity+1

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Not yet recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Squamous cell carcinoma of lung+3

Not yet recruiting

Tislelizumab with drug combination in patients with PD-L1‑high metastatic non‑small cell lung cancer and high tumor burden

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AIO-Studien gGmbH

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Revolution Medicines Inc.

HIV infection

Not yet recruiting

Safety and efficacy of GS-3242 drug combination compared with standard drug combination in treatment‑naive adults with HIV‑1

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Non-small cell lung cancer

Not yet recruiting

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Ischaemic stroke

Not yet recruiting

Enhanced dual antiplatelet therapy with clopidogrel and acetylsalicylic acid for secondary prevention in patients with mild ischemic stroke

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Technische Universitat Dresden

Crohn's disease

Not yet recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Dermatitis atopic

Not yet recruiting

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Neuroendocrine carcinoma

Not yet recruiting

Phase II Study of BI 764532 Added to Platinum Chemotherapy in Adults with Advanced Large‑Cell Neuroendocrine Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Igg-Like T Cell Engager Binding To Dll3 And Cd3
  • Sponsor:Technische Universitat Dresden

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Frankfurt

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on hematologic malignancies and solid tumors, including innovative treatments for lymphoma, leukemia, and various gastrointestinal cancers.

  • Chronic Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Gastric Cancer
  • Pancreatic Cancer

Studies evaluate novel therapeutic combinations and targeted treatments to improve patient outcomes.

02 Gastrointestinal Disorders

Research initiatives examining treatments for inflammatory bowel conditions, including Crohn's Disease and Ulcerative Colitis, with emphasis on long-term management approaches.

  • Moderate to Severe UC
  • Active Crohn's Disease
  • GI Tract Infections

Focus on innovative therapeutic options for chronic inflammatory conditions.

03 Rare Diseases

Clinical investigations of treatments for rare conditions, including Von Willebrand Disease and Dravet Syndrome, exploring novel therapeutic approaches.

  • Blood Disorders
  • Genetic Conditions
  • Neurological Disorders

Development of targeted therapies for previously difficult-to-treat conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.